NCT06879353Completed
Comparison of Single-Dose Tranexamic Acid Vs. Placebo in Ovarian Cancer Surgery
Comparison of Efficacy of Single Dose Tranexamic Acid Versus Placebo Before Surgery in Females Undergoing Surgery for Ovarian Cancer
Source: ClinicalTrials.gov · Last updated 19 Mar 2025
Brief summary (registry, in English)
This study evaluated the effectiveness of a single dose of tranexamic acid compared to a placebo in reducing blood loss and the need for blood transfusions in women undergoing surgery for ovarian cancer. Tranexamic acid, a medication that helps control bleeding by stabilizing blood clots, has been widely used in other surgical settings but has not been well studied in ovarian cancer surgery. Participants were randomly assigned to receive either a single dose of tranexamic acid or a placebo before surgery. Blood loss was measured during and after the procedure, and the need for blood transfusions was recorded. The study aimed to determine whether tranexamic acid was effective in reducing perioperative blood loss and minimizing the need for transfusions. The findings contributed to understanding whether this cost-effective and widely available medication could improve surgical outcomes and reduce complications associated with excessive bleeding in ovarian cancer patients.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 372 (actual)
- First submitted
- 11 Mar 2025
- Start date
- 12 Jul 2023
- Primary completion date
- 12 Jul 2024
- Lead sponsor
- Sheikh Zayed Medical College
- Diseases
- Ovarian cancer
- NCT number
- NCT06879353
What you commit to
- Study type: Interventional
- Participants enrolled: 372
- From 12 Jul 2023 to the primary completion date, 12 Jul 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Hypersensitivity to tranexamic acid, (assessed by reviewing previous medical record).
- History of bleeding or clotting disorders (assessed by reviewing previous medical record).
- History of coronary heart disease (assessed by reviewing previous medical record).
Other illness
- Ovarian cancer of FIGO stage IV
Lab values
- Impaired renal function (serum creatinine \> 1.3 mg/dl).
Other
- ASA status 4-6.
Who the study is looking for
- Age 18-60.
- Female gender.
- Ovarian cancer of \> 12 months duration.
- FIGO stage I-III.
- American Society of Anesthesiologists (ASA) status 1-3.
Age in the registry: 18 years to 60 years · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Sheikh Zayed Medical college/hospital Coordinator of this site? Confirm its status | Rahim Yar Khan | Pakistan | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.